The effect of *Elettaria cardamomum* (cardamom) on the metabolic syndrome: Narrative review

Roghayeh Yahyazadeh 1, Mahboobeh Ghasemzadeh Rahbardar 2, Bibi Marjan Razavi 1,3, Gholamreza Karimi 1,2, Hossein Hosseinzadeh 1,2,*

1 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

**Article type:** Review

**Article history:**
Received: Dec 22, 2020
Accepted: Jul 12, 2021

**Keywords:** Anti-inflammatory agents
Anti-oxidants
*Elettaria cardamomum*
Hypoglycemic agents
Hypolipidemic agents
Metabolic syndrome

**ABSTRACT**

Metabolic syndrome (MetS), as a health-threatening factor, consists of various symptoms including insulin resistance, high blood sugar, hypertension, dyslipidemia, inflammation, and abdominal obesity that raise the risk of diabetes mellitus and cardiovascular disease. Cardiovascular diseases are important causes of mortality among the world population. Recently, there has been a growing interest in using phytomedicine and natural compounds in the prevention and treatment of various diseases. The data was gathered by searching various standard electronic databases (Google Scholar, Scopus, Web of Science, and PubMed) for English articles with no time limitations. All *in vivo*, *in vitro*, and clinical studies were included. *Elettaria cardamomum* (cardamom) is a rich source of phenolic compounds, volatile oils, and fixed oils. Cardamom and its pharmacologically effective substances have shown broad-spectrum activities including antihypertensive, anti-oxidant, lipid-modifying, anti-inflammatory, anti-atherosclerotic, anti-thrombotic, hepatoprotective, hypocholesterolemic, anti-obesity, and antidiabetic effects. This review aims to highlight the therapeutic effects of cardamom on MetS and its components including diabetes, hyperlipidemia, obesity, and high blood pressure as well as the underlying mechanisms in the management of MetS. Finally, it can be stated that cardamom has beneficial effects on the treatment of MetS and its complications.

*Please cite this article as:*
Yahyazadeh R, Ghasemzadeh Rahbardar M, Razavi BM, Karimi GH, Hosseinzadeh H. The effect of *Elettaria cardamomum* (cardamom) on the metabolic syndrome: Narrative review. Iran J Basic Med Sci 2021; 24:1462-1469. doi: https://dx.doi.org/10.22038/IJBMS.2021.54417.12228

**Introduction**

Metabolic syndrome (MetS), as a metabolic disorder, includes a set of major symptoms such as impaired glucose level, dyslipidemia, central obesity, overweight, insulin resistance, and high blood pressure that lead to cardiovascular diseases (CVD), cancer, diabetes mellitus type 2 (DMT2), short lifespan, and low-quality life. MetS has increased concerns about public health problems throughout the world population (1). It is mentioned as a leading public health problem and the cause of morbidity and mortality via high risks for increasing diabetes mellitus and CVD (2-4). Pathophysiology of MetS-induced complications is possibly due to an imbalance in calorie and energy intake associated with alterations in genetic and lifestyle. In addition, it may be affected by the type of food and gut microorganisms (5). Gut microorganisms are sensitive to the changes in nutrition in the intestine and they can also directly participate in the process of absorption (6).

The prevalence of the MetS is not the same in different countries such as the USA (34%), India (25.6%), Kuwait (24.8%), and Australia (22.1%) (7-10). MetS is a threat to human health that requires vital prevention and treatment; thus, effective strategies must be applied to decrease the burden of this disease (11). Because of the side effects and inefficiency of drugs, herbal medicines have been considered for their potential impact on improving and maintaining human health. Medicinal plants and their active constituents such as grapes, saffron, rosemary, garlic, and rutin have long been used to treat various disorders (3, 12-15). Generally, the purpose of spices using in food is to increase the flavor and to take advantage of their medicinal properties (16). Many of the spices belong to herbal families. Therefore, the demand for these herbs has increased because of their beneficial effects on various disorders. Herbal medicines such as *Vitis vinifera* (15), *Silybum marianum* L. (17), *Nigella sativa* (18, 19), *Allium sativum* (12), *Persea americana* (20), *Solana melongena* (21), and *Berberis vulgaris* (22) can ameliorate MetS.

*Elettaria cardamomum* also known as cardamon, belongs to the Zingiberaceae family. It is native to the Indonesia and Indian subcontinent, Pakistan, Burma, Bangladesh, tropical and subtropical Asia. It is perennial, herbaceous monocots with 4-5 m in height. Cardamom flowers are the whitish lip located at the tip of the corolla tube (23). Phytochemical investigations illustrated that *E. cardamomum* contains terpinene, stigmasterol, geranyl acetate, geraniol, β-pinene, citronellol, borneol, bisabolene, eugenyl acetate, phytol, β-sitostenone, neronolid, linalol, α-pinene, menthone, cineol, limonene, subinene, heptane, myrcene, and α-terpineol (24, 25) (Figure 1). The small seeds of cardamom have a triangular pod in cross-section that is covered by a thin papyery black shell (26). Several studies have reported the...
beneficial effects of cardamom on Gram-positive and Gram-negative bacteria (27, 28), teeth and gums health (29), lung disorders (30), and gastrointestinal disorders (31, 32). The therapeutic impacts of cardamom are due to its pharmacological effects including anti-oxidant, antimutagenic (33), antibacterial, anti-inflammatory (34), antidiabetic (35), cardioprotective (36), hepatoprotective, and chemoprotective properties (37).

This review summarizes the potential efficacy of cardamom and its active constituent in MetS and its related complications.

**Methods**

PubMed, Web of Science, Google Scholar, and Scopus databases were used to find articles from 1995 to 2021. The search terms used were “cardamom”, “Elettaria cardamomum”, “hypertension”, “diabetes”, “hyperglycaemia”, “antihyperglycemic”, “antidiabetic”, “blood glucose”, “dyslipidemia”, “hyperlipidemia”, “hypercholesterolemia”; “hyper-triglyceridemia”, “atherosclerosis”, “obesity”, “appetite”, “anti-obesity”, “weight loss”, and “metabolic syndrome”. Our team collected all published *in vivo*, *in vitro* articles, and clinical studies investigating the ameliorative effects of cardamom and its effective constituents on MetS.

**Effect of *E. cardamomum* on dyslipidemia**

Dyslipidemia, which is linked to a changed lipoprotein spectrum and modified lipoproteins, is one of the main risk factors in MetS (38). Increased triglyceride (TG)-rich lipoprotein particles (TRLs), reduced high-density lipoprotein (HDL) and augmented small low-density lipoprotein (LDL) particles are the three major components of dyslipidemia associated with MetS (39). Dyslipidemia plays an important role in developing atherosclerotic CVD associated with MetS. The association between low-density lipoprotein cholesterol (LDL-C) levels and the initiation and development of arterial plaques, for example, is well known, and LDL-lowering therapy has been shown in several clinical trials to substantially reduce the frequency of cardiovascular events. Furthermore, epidemiologic studies have shown that high-density lipoprotein cholesterol (HDL-C) levels and coronary artery disease have a clear inverse relationship (40). Some studies have also stated that the C-reactive protein (CRP) level is a marker for dyslipidemia, diabetes, and MetS (41, 42).

Cardamom and its active ingredients have been demonstrated to modify blood total cholesterol (TC), TG, LDL, and HDL in several investigations.

**Clinical trials**

A clinical trial was carried out on obese or overweight pre-diabetic women taking 3 grams of cardamom for 2 months. The obtained results disclosed that mean TC (from 192.6 to 183.7 mg/dl) and LDL-C (from 118.1 to 110.5 mg/dl) significantly reduced. It also showed a protective effect on HDL-C (from 44.1 to 42.7 mg/dl) amount in pre-diabetic subjects (43). Another study reported that cardamom supplementation (3 g, 10 weeks) could significantly decrease TG (from 158.4 to 125.8 mg/dl) in T2DM patients in comparison with the placebo group (44). A study aimed to assess the cardamom (3 g/day, 8 weeks) effects on inflammation and oxidative stress in hyperlipidemic pre-diabetic women. In comparison to the placebo group, cardamom supplementation significantly reduced serum hs-CRP (from 5.2 to 5.06 mg/dl), hs-CRP/IL-6 ratio (from 775.04 to 623.5), and MDA (from 8.7 to 7.3 μM) level. Cardamom has been shown to control certain inflammatory and oxidative stress parameters in pre-diabetic people. As a result, it may help these patients avoid complications related to inflammation and oxidative stress (45).

**In vivo studies**

Pre-clinical research reported that the administration of cardamom powder suspension in 2% gum acacia (1 g/kg/10 ml, oral, for 12 days) decreased the levels of TC and TG, and increased HDL levels in rats with dexamethasone-induced hepatic steatosis (46). In an

![Active ingredients of cardamom](image_url)
animal study, cardamom oil (3 g/kg, equivalent to 50 g/kg cardamom, 8 weeks, PO) is effective in restoring lipid homeostasis in hypercholesterolemia rats. The substantial reduction in atherogenic index following dietary intervention with cardamom powder and oil suggests that cardamom may have a cardioprotective effect (47).

**In vitro studies**

An *in vitro* study indicated that 1,8-cineole, a constituent of cardamom, exhibited anti-oxidant properties in lipoprotein metabolism and reduced lipid accumulation in THP-1 cells (48).

Cardamom may exhibit its anti-hyperlipidemic effects through the enhanced rate of cholesterol degradative processes or lipoprotein lipase activity, as well as the efficient reduction in lipid absorption from the intestine (Table 1).

**Effect of* E. cardamomum* on obesity**

Obesity is a medical condition in which extra body fat has stored to the point that it can be harmful to one's health. It is characterized by BMI, which is a metric for measuring body fatness (49, 50). Obesity might result in several diseases, including DMT2 (51), cardiovascular disease (52), hypertension (53), as well as respiratory disease (54). Oxidative stress and inflammation have important roles in metabolic disorders linked to obesity (55, 56). According to previous reports, obese patients have lower levels of anti-oxidant markers (superoxide dismutase (SOD), glutathione (GSH) in their blood (55, 57, 58).

Moreover, several parts of the hypothalamus are implicated in the development and maintenance of obesity through several pathways. As one of these important metabolic regulators, sirtuins (SIRTs) are a well-conserved family of class III deacetylases (59). In mammals, seven members of the SIRT family (SIRT1-7) have been identified. SIRT1 is expressed in different organs including the pancreas, liver, adipose tissue, muscle, heart, as well as important metabolic centers of the brain such as the ventromedial hypothalamus (VMH), dorsomedial nucleus, and paraventricular nucleus of the hypothalamus (PVN) (60). SIRT1 regulates body weight by controlling metabolic processes such as food intake, adiposity, energy expenditure, thermogenesis of brown adipose tissue, and browning of white adipose tissue (61, 62). A high-fat diet and obesity result in downregulation of sirtuins especially SIRT1 expression in humans (63). SIRT1 regulates systemic homeostasis by preventing Forkhead box protein 01 (Fox01) acetylation. In the insulin signaling pathway, Fox01 is a downstream transcription factor and its activation or overexpression in the hypothalamus decreases insulin anorexigenic property (64), increases adiposity, and results in weight gain (65).

The anti-obesity effects of cardamom and its active constituents have been stated in numerous studies (Table 2).

**Clinical trials**

An investigation suggested that the administration of cardamom (3 g/day, 3 months) caused an increase in SIRT1 (from 1.2 to 1.3 ng/ml) in the non-alcoholic fatty liver patient (66). Another clinical trial explained that administration of green cardamom (3 g/day, 16 weeks) controlled the expression of some diabetes and obesity genes including fat mass and obesity-associated (FTO), carnitine palmitoyltransferase 1A (CPT1A), leptin receptor, (LEPR), lamin A/C, and peroxisome proliferator-activated receptor gamma (PPAR-γ) in women with polycystic ovary syndrome (67).

**In vivo studies**

It was also found that administration of cardamom powder (1% of powder chow diet w/w, 8 weeks) prevented obesity in high-fat diet-induced obese rats (16).

**Effect of* E. cardamomum* on hypertension**

Hypertension is a metabolic risk factor for CVD. It raises the possibility of numerous CVDs, such as peripheral vascular disease, heart failure, coronary artery disease, and stroke (18).

Several lines of evidence have revealed that cardamom and its active constituents show hypotensive and cardiovascular protective properties.

**Clinical trials**

A study showed that treatment with cardamom (3

---

**Table 1. Therapeutic effects of cardamom and its active constituents on dyslipidemia**

| Compounds                  | Dose                  | Study design                        | Results                                               | Ref |
|----------------------------|-----------------------|-------------------------------------|------------------------------------------------------|-----|
| Cardamom                   | 3g/day, 2 months      | Clinical trial, pre-diabetic women   | ↓TC, ↓LDL-C, ↓Insulin sensitivity                      | (43) |
|                            |                       |                                     | ↓Hba1C, ↓HOMA-IR, ↓TG, ↑SIRT1                        |     |
| Cardamom                   | 3g/day, 10 weeks      | Clinical trial, T2DM patients        | ↓hs-CRP, ↓hs-CRP-JL-4, ↓MDA                           | (44) |
| Cardamom                   | 3g/day, 16 weeks      | Clinical trial, hyperlipidemic, obesity, pre-diabetic women | ↓hs-CRP, ↓TG, ↑SIRT1                                   | (45) |
| Cardamom suspension of 2% gum acacia | 1 g/kg/10 ml, p.o. | In vivo, atherosclerotic rats     | ↓Hepatomegaly, ↓Dyslipidemia                           | (46) |
| Cardamom oil               | 3 g/kg, 8 weeks, p.o. | In vivo, Wistar rats                 | ↓TC, ↓LDL-C, ↓TG                                      | (47) |
| 1,8-cineole                | 10 μg/ml              | In vitro                            | ↓HDL, ↓Lipid accumulation                             | (48) |

TC: total cholesterol, TG: triglyceride, LDL-C: Low-density lipoproteins-cholesterol, T2DM: type 2 diabetes mellitus, Hba1C: hemoglobin A1c, HOME-IR: homeostasis model assessment index, SIRT1: sirtuin-1, hs-CRP: high-sensitivity C-reactive protein, MDA: Malondialdehyde, HDL: high-density lipoprotein

---

Yahyazadeh et al. Cardamom and metabolic syndrome

Iran J Basic Med Sci, Vol. 24, No. 11, Nov 2021
Cardamom and metabolic syndrome

Yahyazadeh et al.

Table 2. Therapeutic effects of cardamom and its active constituents on obesity

| Compounds | Dose | Study design | Results | Ref |
|-----------|------|--------------|---------|-----|
| Cardamom  | two 500 mg capsules, 3 times a day, 3 months | Clinical trial, overweight or obese patients with non-alcoholic fatty liver disease | ↑ SIRT1, ↓ hs-CRP, ↓ TNF-α, ↓ IL-6, ↓ ALT, ↓ Degree of fatty liver | (66) |
| Cardamom  | 3 g/day, 16 weeks | Clinical trial, obese women with polycystic ovary syndrome | ↓ Anthropometric indices, ↑ Glycemic indices, ↓ Expression level of Carnitine palmitoyltransferase 1A, leptin receptor, and lamin A/C, ↑ PPAR-γ | (67) |
| Cardamom  | 3 g/day, 8 weeks | In vivo, male Wistar rats | ↓ Glucose intolerance, ↓ abdominal fat deposition, ↑ Antioxidant enzymes, ↓ ALT, AST and ALP, ↓ Fibrosis in liver | (16) |

SIRT1: sirtuin-1, hs-CRP: high-sensitivity C-reactive protein, TNF-α: Tumor necrosis factor-alpha, ↓ IL-6: Interleukine-6, ALT: alanine aminotransferase, PPAR-γ: peroxisome proliferator-activated receptor gamma, AST: aspartate transaminase, ALP: alkaline phosphatase.

g/day, for 12 weeks) caused a significant decrease in systolic blood pressure (SBP) (from 154.2 to 134.8 mmHg) and diastolic blood pressure (DBP) (from 91.8 to 79.6 mmHg) in individuals with primary hypertension of stage 1. Also, cardamom ameliorated fibrinolysis and improved anti-oxidant status after 3 months (68). In contrast, it has been reported that the administration of cardamom (3 g/day, 8 weeks) did not significantly reduce SBP (from 120.7 to 115.5 mmHg) and DBP (from 78.1 to 77.5 mmHg) in obese pre-diabetic women which might be because of a short intervention period and a small sample size (43).

In vivo studies

An in vivo study showed that cardamom crude extract (3-100 mg/kg) reduced blood pressure by a combination of cholinomimetic and calcium channel blocking mechanisms in rats (69).

It has been reported that α-terpineol (25, 50, or 100 mg/kg/day, a week, PO) was able to attenuate mean arterial pressure in hypertensive rats. The authors suggested that α-terpineol can decrease arterial pressure, probably by decreasing vascular resistance and repairing enzymatic anti-oxidants in these animals (70). These findings reinforce the results of another research that demonstrated that α-terpineol (1, 5, 10, 20 and 30 mg/kg, IV) could induce hypotension and vasorelaxation mediated, partly by the endothelium, probably through releasing NO and activating the NO–cGMP pathway (71). The IV administration of 1,8-cineole (0.3–10 mg/kg) to rats reduced blood pressure, most likely due to active vascular stimulation rather than a reduction of sympathetic tone. These results propose that 1,8-cineole helps to mediate the hypotensive effects of essential oils from certain aromatic plants that are commonly used to treat hypertension (72).

In vitro studies

The vasodilatory effect of cardamom (3-10 mg/ml) has been shown against contraction induced by phenylephrine (1 µM) and potassium (80 mM) in the isolated rat aorta (69). An in vitro study on rabbit aortic endothelial cell line revealed that α-terpineol (10⁻⁹, 10⁻⁸, and 10⁻⁷ mol/l for 15 min) increased nitric oxide (NO) levels via NO–cGMP pathway activation (71).

As a result, different mechanisms such as calcium channel blocking, induction of NOS and endothelial NO, cholinergic effect, and anti-oxidant property are included in the cardioprotective and hypotensive effects of cardamom and its active ingredients (Figure 2). Based on these studies, cardamom is a high potential cardiovascular protective agent (Table 3).

Figure 2. Schematic effect of cardamom and its active component on metabolic syndrome

---

**Figure 2.** Schematic effect of cardamom and its active component on metabolic syndrome.
Cardamom and metabolic syndrome

Yahyazadeh et al. Cardamom and metabolic syndrome

It was also observed that cardamom (3 g, 2 months) could increase insulin sensitivity (from 0.30 to 0.31 QUICKI) in pre-diabetic subjects (43).

In vivo studies

It has been shown that oral administration of cardamom suspension (1 g/kg/10 ml of 2% gum acacia, 6 days before dexamethasone and 6 days during dexamethasone administration (to induce hyperglycemia, dyslipidemia, and hepatic steatosis)) reduced hepatomegaly and hyperglycemia in Albino rats (46). Nanoliposome of 1,8-cineole rich extract of cardamom (550 mg/kg, 35 days) could manage T2DM (83). The hydrolysis of starch by pancreatic α-amylase and the uptake of glucose by intestinal α-glucosidases generate a quick spike in blood glucose levels, which causes hyperglycemia in T2DM patients (84). Therefore, an effective strategy to manage DM is inhibiting intestinal α-glucosidase and α-amylase. An in vitro study on aqueous and methanolic cardamom

| Compounds   | Dose          | Study design                  | Results                                    | Ref |
|-------------|---------------|-------------------------------|--------------------------------------------|-----|
| Cardamom    | 3 g/day, 2 weeks | Clinical trial, individuals with stage 1 hypertension | 1 Lysyl, diastolic and mean blood pressure ↓, Fibrinolytic activity ↑, Anti-inflammatory status ↓ | (68) |
| Cardamom    | 3 g/day, 2 months | Clinical trial, pre-diabetic women | 1 TC, ↓ LDL-C, ↓ Insulin sensitivity | (43) |
| Cardamom    | 3-100 mg/kg   | In vivo, rats                 | 1 Arterial blood pressure ↓, Phenylphthine (1 microM) ↓, induction contractions | (69) |
| α-terpineol | 25, 50, or 100 mg/kg/day, 1 week, PO | In vivo, rats | 1 Mean arterial pressure ↓, Vascular resistance ↑, Anti-oxidant status ↓ | (70) |
| α-terpineol | 1, 5, 10, 20 and 30 mg/kg, IV | In vivo, Wistar rats | 1 Blood pressure ↓, Vasorelaxation ↑ | (71) |
| 1,8-cineole | 0.3-10 mg/kg, IV | In vivo, rats | 1 Mean arterial pressure ↓, Heart rate ↑ | (72) |

TC: total cholesterol, LDL-C: Low-density lipoproteins-cholesterol

Effect of E. cardamomum on hyperglycemia

Hyperglycemia is one of the risk factors of metabolic syndrome. Hyperglycemia can induce vascular inflammation (73), microvascular damage (74), and atherosclerosis (75). It also impairs the immune status by stimulating cell adhesion molecules and inflammatory cytokines besides inhibiting the function of leukocytes (76).

Cardamom can ameliorate high blood glucose, insulin resistance, and glucose metabolic disorders. E. cardamomum and its active constituents can control insulin secretion, insulin resistance through increasing the amount of SIRT1, PPAR-γ coactivator-1 alpha (PGC-1α), and attenuating the function of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) as well as controlling glucose metabolism by inhibiting α-glucosidase and α-amylase.

Relevant studies regarding the effect of cardamom on diabetes, insulin resistance, and glucose metabolism will be discussed below.

Clinical trials

A clinical trial demonstrated that administration of cardamom (3 g/day, 3 months) to a non-alcoholic fatty liver patient caused an increase in SIRT1 (from 1.2 to 1.3 ng/ml) (66). SIRT1 is responsible to regulate insulin secretion, insulin resistance, lipid/glucose/energy metabolism, inflammatory process, CVD, and kidney diseases (77). Moreover, SIRT1 can upregulate PGC-1α that inhibits NF-κB activation. It also impacts obesity, hepatic glucose production, insulin sensitivity (78), inhibits oxidative stress, and inflammation in pancreatic β-cells (79). On the other hand, NF-κB activation in adipose tissue macrophage of liver and muscle adipose tissue can contribute to the development of insulin resistance in these tissues (80). The administration of cardamom (3 g/day, 10 weeks) declined serum hemoglobin-A1C (HbA1C) (from 8.19 to 7.71 %), homeostatic model assessment-insulin resistance (HOMA-IR) (from 5.01 to 3.80), insulin (from 12.8 to 10.7 μIU/ml), TG levels (from 158.4 to 125.8 mg/dl), and elevated SIRT1 level (from 8.73 to 11.10 ng/dl) in overweight/obese T2DM patients (44). It was also observed that cardamom (3 g, 2 months) could increase insulin sensitivity (from 0.30 to 0.31 QUICKI) in pre-diabetic subjects (43).

In vitro studies

It has been reported that supercritical carbon dioxide extract of cardamom increased both the liver insulin sensitivity and glucose uptake in the gut. The results of this study showed that this extract of spices is a safe alternative to metformin and blood glucose regulator-34m (BGR-34) in the treatment of T2DM and could be tested in clinical trials (85). The hydrolysis of starch by pancreatic α-amylase and the uptake of glucose by intestinal α-glucosidases generate a quick spike in blood glucose levels, which causes hyperglycemia in T2DM patients (84). Therefore, an effective strategy to manage DM is inhibiting intestinal α-glucosidase and α-amylase. An in vitro study on aqueous and methanolic cardamom

Table 3. Therapeutic effects of cardamom and its active constituents on hypertension

| Compounds   | Dose          | Study design                  | Results                                    | Ref |
|-------------|---------------|-------------------------------|--------------------------------------------|-----|
| Cardamom    | 3 g/day, 12 weeks | Clinical trial, individuals with stage 1 hypertension | 1 Lysyl, diastolic and mean blood pressure ↓, Fibrinolytic activity ↑, Anti-inflammatory status ↓ | (68) |
| Cardamom    | 3 g/day, 2 months | Clinical trial, pre-diabetic women | 1 TC, ↓ LDL-C, ↓ Insulin sensitivity | (43) |
| Cardamom    | 3-100 mg/kg   | In vivo, rats                 | 1 Arterial blood pressure ↓, Phenylphthine (1 microM) ↓, induction contractions | (69) |
| α-terpineol | 25, 50, or 100 mg/kg/day, 1 week, PO | In vivo, rats | 1 Mean arterial pressure ↓, Vascular resistance ↑, Anti-oxidant status ↓ | (70) |
| α-terpineol | 1, 5, 10, 20 and 30 mg/kg, IV | In vivo, Wistar rats | 1 Blood pressure ↓, Vasorelaxation ↑ | (71) |
| 1,8-cineole | 0.3-10 mg/kg, IV | In vivo, rats | 1 Mean arterial pressure ↓, Heart rate ↑ | (72) |

TC: total cholesterol, LDL-C: Low-density lipoproteins-cholesterol
extracts showed that these extracts have α-glucosidase and α-amylase inhibitory effects and can be used in managing diabetes (35).

It can be suggested that cardamom and its active ingredients disclose their therapeutic or preventive properties against diabetes via several mechanisms including decreasing glucose level, insulin resistance, increasing insulin level, glucose uptake, anti-oxidant effects, and the number of β-cells in the pancreas (Table 4) (Figure 2). However, there are not enough clinical studies on the effectiveness of cardamom in diabetes. Therefore, more human studies should be performed on the preventive or curative effect of this herb on diabetes.

**Conclusion**

This manuscript reviewed the chief aspects of MetS and protective mechanisms of *E. cardamomum* and its active constituents in ameliorating and attenuating the components of MetS including dyslipidemia (by increasing the rate of cholesterol degradation, activating lipoprotein lipase, reducing lipid absorption from the intestine), obesity (through increasing the amount of SIRT1 and controlling some genes involved in obesity), hypertension (via blocking calcium channels, induction of cholinergic effects and anti-oxidant property), and high blood glucose (by enhancing the amount of SIRT1, PGC-1α, reducing NF-κB and high blood glucose), and increasing the rate of cholesterol degradation, activating lipoprotein lipase, reducing lipid absorption from the intestine, increasing the number of β-cells in the pancreas (Table 4) (Figure 2). However, there are not enough clinical studies on the effectiveness of cardamom in diabetes. Therefore, more human studies should be performed on the preventive or curative effect of this herb on diabetes.

**Table 4. Therapeutic effects of cardamom and its active constituents on diabetes**

| Compounds                        | Dose                  | Study design          | Results                                      | Ref  |
|----------------------------------|-----------------------|-----------------------|----------------------------------------------|------|
| Cardamom                         | 3 g/day, 10 weeks     | Clinical trial, 720M patients | HbA1C ↓ glucosidase activity ↓ amylase activity | (44) |
| Supercritical carbon dioxide extract of cardamom seeds | 550 mg/kg, 35 days, PO | In vivo, Wistar Albino rats | Fasting blood sugar ↑ glucose uptake in the gut | (81) |
| Supercritical carbon dioxide extract of cardamom seeds | 1 mg/ml | In vitro | Insulin sensitivity ↑ glucoside activity ↓ amylase activity | (35) |
| Aqueous and methanol extract of cardamom extracts | In vitro | In vitro | Fasting blood sugar ↑ HbA1C ↓ insulin ↓ cholesterol uptake in the gut | (44) |

HbA1C: hemoglobin A1c, HOMA-IR: homeostasis model assessment index, TG: triglyceride, SIRT1: sirtuin-1.

**References**

1. Mallazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci 2016; 19: 1258–1270.
2. Tousian Shandiz H, Razavi BM, Hosseinzadeh H. Review of *Garcinia mangostana* and its xanthones in metabolic syndrome and related complications. Phytother Res 2017; 31: 1173-1182.
3. Hassani FV, Shiri K, Hosseinzadeh H. Rosemary (*Rosmarinus officinalis*) as a potential therapeutic plant in metabolic syndrome: a review. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 931-949.
4. Baxter AJ, Coyne T, McClinton C. Dietary patterns and metabolic syndrome-a review of epidemiologic evidence. Asia Pac J Clin Nutr 2006; 15: 134-142.
5. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20: 1-8.
6. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JL, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65.
7. Beigh SH, Jain S. Prevalence of metabolic syndrome and gender differences. Bioinformation 2012; 8: 613-616.
8. Al Rashdan I, Al Nesef Y. Prevalence of overweight, obesity, and metabolic syndrome among adult Kuwaitis: results from community-based national survey. Angiology 2010; 61: 42-48.
9. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over; by sex, age, race and ethnicity, and body mass index. United States, 2003-2006. Natl Health Stat Report 2009; 1-7.
10. Janus ED, Laatikainen T, Dunbar JA, Kilkkinen A, Bunker SJ, Philpot B, et al. Overweight, obesity and metabolic syndrome in rural southeastern Australia. Med J Aust 2007; 187: 147-152.
11. Magkos F, Yannakoulia M, Chan JL, Mantzoros CS. Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 2009; 29: 223-256.
12. Hosseini A, Hosseinzadeh H. A review on the effects of *Allium sativum* (Garlic) in metabolic syndrome. J Endocrinol Invest 2015; 38: 1147-1157.
13. Hosseinzadeh H, Nassiri-Asl M. Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J Endocrinol Invest 2014; 37: 783-788.
14. Razavi BM, Hosseinzadeh H. Saffron: a promising natural medicine in the treatment of metabolic syndrome. J Sci Food Agric 2017; 97: 1679-1685.
15. Akaber M, Hosseinzadeh H. Grapes (*Vitis vinifera*) as a potential candidate for the therapy of the metabolic syndrome. Phytother Res 2016; 30: 540-556.
16. Rahman MM, Alam MN, Ulla A, Sumi FA, Subhan N, Khan...
T, et al. Cardamom powder supplementation prevents obesity, improves glucose intolerance, inflammation and oxidative stress in liver of high carbohydrate high fat diet induced obese rats. Lipids Health Dis 2017; 16: 1-12.

17. Vahabzadeh M, Amiri N, Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric 2018; 98: 4816-4823.

18. Razavi B, Hosseinzadeh H. A review of the effects of *Nigella sativa* L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014; 37: 1031-1040.

19. Fadishei M, Ghasemzadeh Rahbar M, Hosseinshahidi M, Mohajeri A, Razavi BM, Hosseinzadeh H. Effects of *Nigella sativa* oil and thymoquinone against bisphenol A-induced metabolic disorder in rats. Phytother Res 2021; 35: 2005-2024.

20. Tabeshpour J, Razavi BM, Hosseinzadeh H. Effects of avocado (*Persea americana*) on metabolic syndrome: A comprehensive systematic review. Phytother Res 2017; 31: 819-837.

21. Yarmohammadi F, Ghasemzadeh Rahbar M, Hosseinzadeh H. Effect of eggplant (*Solanum melongena*) on the metabolic syndrome: A review. Iran J Basic Med Sci 2021; 24: 420-427.

22. Tabeshpour J, Imenshahidi M, Hosseinzadeh H. A review of the effects of *Berberis vulgaris* and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci 2017; 20: 557-568.

23. Ravindran P, Madhusoodanan K. Cardamom: the genus *Elettaria*: CRC Press; 2002.

24. Gopalakrishnan M, Narayanan C, Grenz M. Non-saponifiable lipid constituents of Cardamom. J Agric Food Chem 1990; 38: 2133-2136.

25. Duke JA. Handbook of phytochemical constituent grass, herbs and other economic plants. CRC press LLC; 1992.p. 239-240.

26. Anwar F, Abbas A, Alkhafry KM. Cardamom. (*Elettaria cardamomum* Maton) Oils. In: Preedy VR, editor. Essential oils in food preservation, flavor and safety. Academic Press; 2016.p. 295-301.

27. Alam A, Rehman NU, Ansari MN, Palla AH. Effects of essential oils of *Elettaria cardamomum* grown in India and Guatemala on gram-negative bacteria and gastrointestinal disorders. Molecules 2021; 26: 2546.

28. Kaushik P, Goyal P, Chauhan A, Chauhan G. *In vitro* evaluation of antibacterial potential of dry fruit extracts of *Elettaria cardamomum* Maton (Chhoti Elaichi). Iran J Pharm Sci 2010; 9: 287-292.

29. Jesylne P, Soundarajan S, Murthykumar K, Meenakshi M. *Elettaria* cardamomum (Chhoti Elaichi). In: Preedy VR, editor. Essential oils and other economic plants. CRC press LLC; 1992.p. 239-240.

30. Kumari S, Dutta A. Protective effect of *Elettaria cardamomum* (L.) Maton against Pan masala induced damage in lung of male Swiss mice. Asian Pac J Trop Med 2013; 6: 525-531.

31. Al-Zuhair H, El-Sayeh B, Ameen H, Al-Shoora H. Pharmacological studies of cardamom oil in animals. Pharmacol Res 1996; 34: 79-82.

32. Jamal A, Javed K, Aslam M, Jafri M. Gastroprotective effect of cardamom oil and thymoquinone against isoproterenol-induced myocardial infarction in rats. Int J Mol Sci 2015; 16: 27457-27469.

33. Elguindy NM, Yacouat GA, El Azab EF, Maghary HB. Chemoprotective effect of *Elettaria cardamomum* against chemically induced hepatocellular carcinoma in rats by inhibiting NF-xB, oxidative stress, and activity of ornithine decarboxylase. S Afr J Bot 2016; 105: 251-258.

34. Blaton VH, Korita I, Bulo A. How is metabolic syndrome related to dyslipidemia? Biochem Med 2008; 18: 14-24.

35. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500.

36. Celufu WT. Diabetic dyslipidemia and the metabolic syndrome. Diabetes Metab Syndr 2008; 2: 208-222.

37. Jeong H, Baek SY, Kim SW, Park EJ, Lee J, Kim H, et al. C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ open 2019; 9: e029861.

38. den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salomé PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol 2012; 11: 1-7.

39. Fatemeh Y, Siassi F, Rahimi A, Khoohdani F, Doostan F, Qorbani M, et al. The effect of cardamom supplementation on serum lipids, glyemic indices and blood pressure in overweight and obese pre-diabetic women: a randomized controlled trial. J Diabetes Metab Disord 2017; 16: 1-9.

40. Aghasi M, Khoohdani F, Qorbani M, Nasli-Esfahani E, Ghaizi-Zahedi S, Khoshhamal H, et al. Beneficial effects of green cardamom on serum SIRT1, glyemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial. J Sci Food Agric 2019; 99: 3933-3940.

41. Kazemi S, Yaghoooblu F, Siassi F, Rahimi Foroushani A, Ghaviour M, Khoohdani F, et al. Cardamom supplementation improves inflammatory and oxidative stress biomarkers in hyperlipidemic, overweight, and obese pre-diabetic women: A randomized controlled trial. J Sci Food Agric 2017; 97: 5296-5301.

42. Bhat GN, Nayak N, Vinodraj K, Chandralekha N, Mathai P, Cherian J. Comparison of the efficacy of cardamom (*Elettaria cardamomum*) with pioglitazone on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in albino rats. J Adv Pharm Technol Res 2015; 6: 136-140.

43. Nagashree S, Archana KK, Srinivas P, Srinivasan K, Sowbhagya HB. Anti-hypercholesterolemic influence of the spice cardamom (*Elettaria cardamomum*) in experimental rats. J Sci Food Agric 2017; 97: 3204-3210.

44. Cho K-H. 1, 8-cineole protected human lipoproteins from oxidation and glycation and exhibited serum antioxidative activity in vitro. J Nutr Biochem 2016; 27: 27457-27469.

45. Razavi B, Hosseinzadeh H. Carnosic acid prevented olanzapine-induced metabolic modification by oxidation and glycation and exhibited serum antioxidative activity in vitro. J Nutr Biochem 2016; 27: 27457-27469.

46. Fadishei M, Ghasemzadeh Rahbar M, Hosseinzadeh H. Effect of cardamom supplementation on *Elettaria cardamomum* and *Nigella sativa* L. on metabolic syndrome: A review. Iran J Basic Med Sci 2021; 24: 819-837.  

47. Fadishei M, Ghasemzadeh Rahbar M, Hosseinzadeh H. Effect of *Elettaria cardamomum* and its major component, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014; 37: 1031-1040.  

48. Elguindy NM, Yacouat GA, El Azab EF, Maghary HB. Chemoprotective effect of *Elettaria cardamomum* against chemically induced hepatocellular carcinoma in rats by inhibiting NF-xB, oxidative stress, and activity of ornithine decarboxylase. S Afr J Bot 2016; 105: 251-258.  

49. Blaton VH, Korita I, Bulo A. How is metabolic syndrome related to dyslipidemia? Biochem Med 2008; 18: 14-24.  

50. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500.
disorders in rat. Iran J Basic Med Sci 2019; 22: 1476-1482.
51. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 2016; 118: 1723-1735.
52. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res 2016; 118: 1752-1770.
53. Jiang SZ, Lu W, Zong XF, Ruan HY, Liu Y. Obesity and hypertension. Exp Ther Med 2016; 12: 2395-2399.
54. Xanthopoulos M, Tapias E. Obesity and common respiratory diseases in children. Paediatr Respir Rev 2017; 23: 68-71.
55. Malti N, Merzouk H, Merzouk S, Loukidi B, Karouzene N, Malti A, et al. Oxidative stress and maternal obesity: fetoplacental unit interaction. Placenta 2014; 35: 411-416.
56. Shoelson SE, Herrero L, Naa Z. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-2180.
57. Madhikarmi NL, Singh PP, Khatun T. Lipid peroxidation and anti-oxidant status in male and female patients with type 1 and type 2 diabetes mellitus. Med PHoeniX 2016; 118: 10-14.
58. Mohlnar D, Decsi T, Koletzko B. Reduced anti-oxidant status in obese children with multimetabolic syndrome. Int J Obes 2004; 28: 1197-1202.
59. Quinones M, Martinez-Grobas E, Fernes J, Perez-Lois R, Seoane LM, Al Massadi O. Hypothalamic actions of SIRT1 and SIRT6 on energy balance. Int J Mol Sci 2021; 22: 1430.
60. Al Massadi O, Quinones M, Lear P, Dieguez C, Nogueiras R. The brain: A new organ for the metabolic actions of SIRT1. Horm Metab Res 2013; 45: 960-966.
61. Ramadori G, Fujikawa T, Fukuda M, Anderson J, Morgan DA, Mosloslavsky R, et al. SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against diet-induced obesity. Cell Metab 2010; 12: 78-87.
62. Velasquez DA, Martinez G, Romero A, Vazquez MJ, Boit KD, Dopenes-Reyes IG, et al. The central sirtuin 1/p38 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011; 60: 1177-1185.
63. dos Santos Costa C, Hammes TO, Rohden F, Margis R, Bortolotto W, Padoin AV, et al. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis. Obes Surg 2010; 20: 633-639.
64. Kim M-S, Pak YK, Jang P-G, Namkoong C, Choi Y-S, Won J-C, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci 2006; 9: 901-906.
65. Susanti YV, Sasaki T, Yokota-Hashimoto H, Matsui S, Lee YS, J-C. SIRT1 transcription is decreased in hypothalamic Foxo1 in POMC neurons of male mice. Obesity 2014; 22: 2115-2119.
66. Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, et al. SIRT1 transcription is decreased in hypothalamic Foxo1 in POMC neurons of male mice. Obesity 2014; 22: 2115-2119.
67. Cheshmeh S, Elahi N, Ghayyem M, Mosayebi E, Moradi S, Alavian SM, Badri-Fariman M, et al. SIRT1 transcription is decreased in hypothalamic Foxo1 in POMC neurons of male mice. Obesity 2014; 22: 2115-2119.
68. Verma S, Jain V, Katewa S. Blood pressure lowering, fibrinolysis enhancing and anti-oxidant activities of cardamom (Elettaria cardamomum). Indian J Biochem Biophys 2009; 46: 503-506.
69. Gilani AH, Jabeen Q, Khan A-U, Shah AJ. Gut modulatory, blood pressure lowering, diuretic and sedative activities of cardamom. J Ethnopharmacol 2008; 115: 463-472.
70. Sabino CKB, Ferreira-Filho ES, Mendes MB, da Silva-Filho JC, Ponte MPTR, Moura LHP, et al. Cardiovascular effects induced by α-terpineol in hypertensive rats. Flavour Fragr J 2013; 28: 333-339.
71. Ribeiro TP, Porto DL, Menezes CP, Antunes AA, Silva DF, De Sousa DP, et al. Unravelling the cardiovascular effects induced by α-terpineol: A role for the nitric oxide–cGMP pathway. Clin Exp Pharmacol Physiol 2010; 37: 811-816.
72. Lahouli S, Figueiredo AF, Magalhães PJ, Leal-Cardoso JH. Cardiovascular effects of 1, 8-cineole, a terpenoid oxide present in many plant essential oils, in normotensive rats. Can J Physiol Pharmacol 2002; 80: 1125-1131.
73. Dandona P, Aljada A, Bandypadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
74. Du X, Edelstein D, Obici S, Higham N, Zou M-H, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. The Journal of clinical investigation 2006; 116: 1071-1080.
75. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clinical cornerstone 2007; 8: 530-542.
76. Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocrine Practice 2006; 12: 22-26.
77. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with PPARα to prevent the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 2011; 90: 276-284.
78. Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 2013; 37: 315-325.
79. Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 2013; 37: 315-325.
80. Baker RG, Hayden MS, Ghosh S. NF-xB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22.
81. Paul K, Bhattacharjee P, Chatterjee N, Paul TK. Nanoliposomes of supercritical carbon dioxide extract of small cardamom seeds redresses type 2 diabetes and hypercholesterolemia. Recent Pat Biotechnol 2019; 13: 284-303.
82. Gomaa AA, Makboul RM, El-Mokhtar MA, Abdel-Rahman EA, Ahmed IA, Nicola MA. Terpenoid-rich Elettaria cardamomum extract prevents Alzheimer-like alterations induced in diabetic rats via inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines. Cytokine 2019; 113: 405-416.
83. Paul K, Chakraborty S, Mallick P, Bhattacharjee P, Pal TK, Chatterjee N, et al. Supercritical carbon dioxide extracts of small cardamom and yellow mustard seeds have fasting hypoglycaemic effects: diabetic rat, predictive iHOMA2 models and molecular docking study. Br J Nutr 2021; 125: 377-388.
84. Mohamed EAH, Siddiqui MJA, Ang LF, Sadiuk A, Chan SH, Tan SC, et al. Potent α-glucosidase and α-amylase inhibitory activities of standardized 50% ethanolic extracts and sinensetin from Ortosiphon stamineus Benth as anti-diabetic mechanism. BMC Complement Altern Med 2012; 12: 1-7.